Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 100%High 0 · 0%

Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin

Progression‐free survival · first‐line treatment of ovarian cancer

Weekly paclitaxel plus carboplatin probably leads to lower progression‐free survival (PFS) compared with tri‐weekly paclitaxel plus carboplatin (moderate certainty).

1 finding from 1 review

Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
HR 0.89 [0.81, 0.98]
4 studies · 3699 participants
Moderate